TFAM and breast carcinoma: Moreover, Ki8751, a vascular endothelial growth factor (VEGF) receptor 2 inhibitor, induces ROS generation and apoptosis of breast cancer cells by decreasing the phosphorylation of AKT and peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α), which improves the nucleus translocation of PGC1α and mitochondrial transcription factor A (TFAM) expression, and mitochondrial biogenesis [173].